Author Archive: Daniel Seaton

Daniel Seaton

Daniel Seaton is Manager of Event & Health Communications, working on communications for BIO’s events and health care policy issues. Prior to joining BIO in August 2013, he spent four years in communications at the Pharmaceutical Research and Manufacturers of America. The best part of his job is educating audiences about the many benefits the bioscience industry produces for patients, consumers, and the economy as a whole. Daniel enjoys hiking, camping, and, when he can find a game, playing bridge. Having grown up in New Mexico, one of his favorite foods is roasted green chile. He is currently finishing up a Master’s degree in communications at Georgetown University.

Latest Posts

U-T San Diego Commentary: Lack of Preparedness to Ebola Is Symptom of Larger Disease

admin-ajax

Last week, the U-T San Diego published an op-ed by Betrand Liang, CEO of Pfenex Inc., a BIO member, arguing that our current lack of vaccines and therapies for Ebola is a symptom of a larger problem. That problem, Liang argues, is a lack of funding for critical biodefense programs which Congress passed in 2004 as a way to prepare us for biological agents like anthrax, smallpox, and Ebola, as well as chemical, radiological, and Read More >

Health  |  Leave a comment  |  Email This Post
Tags: , , , , , ,

Flu Season: Get Vaccinated Now to Ensure Protection

Vaccination

With flu season – and holiday travel – just around the corner, right now is a good time to get an annual flu vaccine (whether you opt for a shot or the nasal spray), which is the best way to prevent yourself from becoming infected with the flu. Flu season in America most commonly peaks between December and January. It typically takes about two weeks after you are vaccinated for protective antibodies to build up Read More >

Health  |  Leave a comment  |  Email This Post
Tags: , , , ,

Kenneth Thorpe: America Subsidizes Medical Innovation for World

Test Tubes

Kenneth Thorpe, chairman of the Partnership to Fight Chronic Disease and a former deputy assistant secretary for Health Policy at HHS, wrote a post for The Hill this week pointing out what is left unstated in many current discussions about the price of innovative medicines and treatments: other nations aren’t paying their fair share for medical advancements, driving up the costs here at home: Patients throughout the globe benefit from the pharmaceuticals, medical devices and Read More >

Health  |  Leave a comment  |  Email This Post
Tags: , ,

BIO Investor Forum Closing Plenary: How Fragile is the Biotech Rally After Five Positive Years?

2

Last week’s 13th Annual BIO Investor Forum closed on Wednesday with a plenary session asking, “How fragile is the biotech rally after five positive years?” Moderated by Todd Foley, Managing Director, MPM Capital, the panel included: Rachel King, CEO, GlycoMimetics and Chair, BIO Ellen Lubman, VP Strategy and Innovation, Forest Laboratories Vijay Murthy, Director, Ventures and Early Stage Collaborations, AbbVie Michael A. Margolis, RPh, Managing Director, ROTH Capital Partners Doug Fambrough, PhD, CEO, Dicerna Pharmaceuticals Read More >

Business of Biotech  |  Leave a comment  |  Email This Post
Tags: , , ,

Gene Therapies Discussed at 2014 BIO Investor Forum

BIO Investor Forum

Since the great excitements and disappointments of gene therapy’s first clinical era, the 1990s, researchers have revised traditional approaches and developed innovative new techniques, including CRISPR/cas-9, to edit genes with greater speed and precision than ever before.  Across a wide range of diseases, gene therapy is showing traction with fresh clinical results and attracting more than $600 million in venture capital in the past two years.  However, real challenges remain in delivery of therapies in Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , , , , ,